140 related articles for article (PubMed ID: 15740661)
1. Unusual prostate carcinoma characterized by extensive metastasis, significantly increased serum level of prostatic-specific antigen,and neuroendocrine differentiation: a case report.
Hu YX; Ye J; Jiang Y; Zhang QF; Wu YL; Chen YY
Chin Med J (Engl); 2005 Feb; 118(3):258-61. PubMed ID: 15740661
[No Abstract] [Full Text] [Related]
2. [Prostatic adenocarcinoma with neuroendocrine differentiation of the small cell type].
Rimoldi DA; Antonio Costa J; Roveto S; Rivero O
Medicina (B Aires); 2001; 61(3):322-4. PubMed ID: 11474882
[TBL] [Abstract][Full Text] [Related]
3. Submandibular area metastasis from prostate small cell carcinoma with neuroendocrine differentiation.
Xiao WL; Zhou FT; Feng YY; Li NY
J Craniofac Surg; 2007 Sep; 18(5):1155-7. PubMed ID: 17912103
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine differentiation in prostatic carcinoma: an update.
di Sant'Agnese PA
Prostate Suppl; 1998; 8():74-9. PubMed ID: 9690666
[TBL] [Abstract][Full Text] [Related]
5. Relapsed prostate cancer with neuroendocrine differentiation and high serum levels of carcinoembryonic antigen without elevation of prostrate-specific antigen: a case report.
Kinebuchi Y; Noguchi W; Irie K; Nakayama T; Kato H; Nishizawa O
Int J Urol; 2007 Feb; 14(2):147-9. PubMed ID: 17302572
[TBL] [Abstract][Full Text] [Related]
6. Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome.
Dawson NA; McLeod DG
J Urol; 1995 Jun; 153(6):1946-7. PubMed ID: 7538601
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
8. Prostatic meningeal carcinomatosis with low serum level of prostate-specific antigen.
Honda M; Miyagawa I
Urology; 2005 Dec; 66(6):1320. PubMed ID: 16360475
[TBL] [Abstract][Full Text] [Related]
9. Small cell carcinoma of the prostate with hypercalcemia.
Hanazawa K; Higashi N; Kawachi Y; Suzuki F; Ishi K; Fujime M
Int J Urol; 2005 Jan; 12(1):108-10. PubMed ID: 15661065
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine differentiation in prostate cancer: from lab to bedside.
Cindolo L; Cantile M; Vacherot F; Terry S; de la Taille A
Urol Int; 2007; 79(4):287-96. PubMed ID: 18025844
[TBL] [Abstract][Full Text] [Related]
11. Small-cell neuroendocrine carcinoma as a variant form of prostate cancer recurrence: a case report and short literature review.
Yashi M; Terauchi F; Nukui A; Ochi M; Yuzawa M; Hara Y; Morita T
Urol Oncol; 2006; 24(4):313-7. PubMed ID: 16818183
[TBL] [Abstract][Full Text] [Related]
12. Neuroendocrine differentiation in prostate cancer.
Shariff AH; Ather MH
Urology; 2006 Jul; 68(1):2-8. PubMed ID: 16844446
[No Abstract] [Full Text] [Related]
13. Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy.
May M; Siegsmund M; Hammermann F; Loy V; Gunia S
Scand J Urol Nephrol; 2007; 41(5):375-81. PubMed ID: 17853019
[TBL] [Abstract][Full Text] [Related]
14. Skin metastasis of prostate adenocarcinoma to glans penis showing no correlation with serum prostate-specific antigen level.
Kobashi-Katoh R; Tanioka M; Takahashi K; Miyachi Y
J Dermatol; 2009 Feb; 36(2):106-8. PubMed ID: 19284456
[No Abstract] [Full Text] [Related]
15. Neuroendocrine differentiation of localized prostate cancer during endocrine therapy.
Nemoto K; Tomita Y
Scand J Urol Nephrol; 2007; 41(6):558-60. PubMed ID: 17853028
[TBL] [Abstract][Full Text] [Related]
16. Breast metastasis from prostate cancer and interpretation of immunoreactivity to prostate-specific antigen.
Cheng CW; Chan LW; Ng CF; Chan CK; Tse MK; Lai MM
Int J Urol; 2006 Apr; 13(4):463-5. PubMed ID: 16734876
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level.
Leibovici D; Spiess PE; Agarwal PK; Tu SM; Pettaway CA; Hitzhusen K; Millikan RE; Pisters LL
Cancer; 2007 Jan; 109(2):198-204. PubMed ID: 17171704
[TBL] [Abstract][Full Text] [Related]
18. Skewing towards neuroendocrine phenotype in high grade or high stage androgen-responsive primary prostate cancer.
Puccetti L; Supuran CT; Fasolo PP; Conti E; Sebastiani G; Lacquaniti S; Mandras R; Milazzo MG; Dogliani N; De Giuli P; Fasolis G
Eur Urol; 2005 Aug; 48(2):215-21; Discussion 221-3. PubMed ID: 15992991
[TBL] [Abstract][Full Text] [Related]
19. [Recrudescence of prostate cancer with low serum level of PSA and high serum level of CEA and CA19-9: a case report].
Yokoyama S; Fukuhara S; Imazu T; Hara T; Yamaguchi S; Adachi S
Hinyokika Kiyo; 2007 Jul; 53(7):485-7. PubMed ID: 17702183
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of neuroendocrine differentiation in carcinoma of the prostate.
Dema A; Raica M; Tudose N
Rom J Morphol Embryol; 1996; 42(1-2):83-8. PubMed ID: 9038390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
